Physician profile
Timothy Wilson
NPI 1912005422
$108,539.39
in general payments reported to CMS, 2019-2025
31 companies · $9,400 in 2025
The $9,400 reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,703 · 2020: $12K · 2021: $7,827 · 2022: $25K · 2023: $35K · 2024: $13K · 2025: $9,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $9,441 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,150 · Food and Beverage: $3,029 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,420.00 |
| Travel and Lodging | $9,441.05 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,150.00 |
| Food and Beverage | $3,029.13 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $74,572.29 | 2019-2025 | |
| Amniox Medical, INC. | $14,750.00 | 2019-2020 | |
| Intuitive Surgical, INC. | $6,753.20 | 2019-2023 | Da Vinci Surgical System |
| Regeneron Pharmaceuticals, INC. | $3,450.00 | 2021 | |
| Angiodynamics, INC. | $2,412.02 | 2023-2025 | Nanoknife |
| Osiris Therapeutics INC. | $2,121.43 | 2019 | |
| Edap Technomed INC | $2,016.67 | 2021-2023 | |
| Smith+Nephew, INC. | $810.98 | 2019-2023 | Stravix |
| Conmed Corporation | $244.05 | 2020-2022 | |
| Urogen Pharma, INC. | $207.52 | 2022-2024 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $203.76 | 2021-2023 | |
| Dendreon Pharmaceuticals LLC | $176.94 | 2019-2025 | Provenge |
| Merck Sharp & Dohme LLC | $167.97 | 2019-2021 | |
| Clinical Laserthermia Systems Americas INC. | $127.07 | 2022 | |
| Seagen INC. | $89.99 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.01 | 2024-2025 | |
| Boston Scientific Corporation | $46.61 | 2022-2023 | Rezum Generator |
| Progenics Pharmaceuticals, INC. | $40.86 | 2022-2023 | Pylarify |
| Abbvie INC. | $40.65 | 2022 | |
| Amgen INC. | $39.90 | 2021-2023 | Xgeva |
| Lilly USA, LLC | $33.37 | 2024 | Retevmo, Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2023 | Opdivo |
| Emd Serono, INC. | $23.02 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $22.27 | 2019 | |
| Coloplast Corp | $19.22 | 2020 | |
| Astellas Pharma US INC | $18.65 | 2021 | |
| Endo Pharmaceuticals INC. | $18.48 | 2022 | |
| Baxter Healthcare | $17.69 | 2022 | |
| Myriad Genetic Laboratories, INC. | $16.69 | 2024 | Prolaris |
| Blue Earth Diagnostics | $14.39 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.